Skip to content
  • Home
  • AboutAbout
    • Why NASP
    • Join NASP
    • Member Benefits
    • Leadership
    • Corporate Members
    • Committees
    • SASP
  • Annual ConferenceAnnual Conference
    • inSPire2026 Event Site
    • Abstracts & Posters
    • NASP Industry Awards
    • We can’t wait to inSPire YOU!
  • NASP UniversityNASP University
    • NASP University Resources
    • NASP Education Center
    • 2025 CSP Exam Prep Course
    • NASP Scholarship
    • Webinars
  • CertificationCertification
    • Becoming Certified
    • Maintaining Certification
    • Handbook
    • SPCB Leadership
    • CSP Credential Verification
    • Apply Now/Login to Account
  • AdvocacyAdvocacy
    • Speaking with One Voice
    • Public Policy Advocacy
    • ProtectSpecialtyPharmacy.com
  • News & ResourcesNews & Resources
    • 2024 Digital Patient Engagement (DPE) Survey Results
    • NASP News
    • Member Insights
    • Marketplace
    • Job Board
    • Patient Satisfaction Survey Program
    • Postgraduate Opportunity Board
    • The Specialty Pharmacy Difference
    • Specialty Pharmacy SmartBrief
Sign In Join Now

Advocacy Resources

  • NASP comments on the OIG HHS proposed regulation
    NASP comments on the Office of Inspector General (OIG) Department of Health & Human Services (HHS) proposed regulation, “Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees.” [84 Fed. Reg. No. 25, February 6, 2019; OIG-0936-P; RIN 0936-AA08.]
  • NASP comments on CMS proposed regulation
    NASP comments on Centers for Medicare and Medicaid Services (CMS) proposed regulation, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses.” [83 Fed. Reg. No. 231, November 30, 2018; CMS-4180-P; RIN 0938-AT92.]
  • HHS ANPRM on the IPI Model for Medicare Part B Drugs
  • NASP comments on HHS Blueprint and Request for Information
  • A Tangled Web: An Examination of the Drug Supply and Payment Chains
  • Medicare Program 2019 Policy and Technical Changes
    Medicare Program: Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program
  • Announcement of Calendar Year 2019 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter
  • CMS Finalizes Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-F]
  • 2019 Medicare Advantage and Part D Rate Announcement and Call Letter
  • NASP comments to CMS Proposed Rule and 2019 Draft Call Letter
  • CMS Proposed Rule on Part D – November 16, 2017
  • NASP comments to CMS Proposed Medicare Part D DIR Reporting Requirements for 2016
  • NASP Response to the 2017 Transformation Ideas in Response to Final Part D Call Letter’s Request for Information (RFI)
  • NASP Response Advance Notice of Methodological Changes for Calendar Year (201) for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 201 Call Letter
  • Any Willing Pharmacy (AWP) Changes Are Needed to Improve Beneficiary Access to Specialty Pharmacies
  • Overview of AWP Provisions for 2017 Contract Year
  • Overview of 2017 Direct and Indirect Remuneration Fees
  • DIR Fees Increase Medicare Beneficiary and Medicare Program Costs for Specialty Drugs
  • NASP Definitions of Specialty Pharmacy and Specialty Medications

Proud members of:

ASAE, CCP, PQA

National Association of Specialty Pharmacy

300 New Jersey Ave NW #900
Washington, DC 20001

703.842.0122

Job Board FAQ Contact
NASP on Facebook   NASP on Twitter   NASP on LinkedIn  
Bylaws Privacy Terms of Use